The Classic Egg-Yolk Macular Dystrophy of Childhood
A photograph developing in a darkroom doesn't reveal its final image all at once — it emerges gradually, through a series of distinct stages, from a faint impression to something fully formed. Best disease unfolds beneath the macula in a comparable way: a rounded, golden-yellow deposit appears first as a smooth, whole shape, then breaks apart over a period of years, before eventually settling into its final form. The name vitelliform, drawn from the Latin word for egg yolk, simply describes what that early deposit looks like, and it's this staged unfolding, more than any single symptom, that shapes how the condition is followed over time.
One detail regularly catches Zambian families off guard at a first consultation: a child can carry a strikingly visible yolk-shaped lesion on examination and still read comfortably at their expected level. The appearance of the lesion and a person's actual vision simply don't always move together, which is exactly why correctly staging the disease carries far more weight than reacting to how dramatic the retinal photograph looks.
During the earliest, intact stage, central vision is often only mildly affected — sometimes not affected at all — despite the lesion itself being unmistakable on examination. Symptoms tend to become noticeable once that once-smooth deposit begins to break apart, a stage often likened to a scrambled egg; this is typically when blurred or distorted central vision, along with difficulty with fine print, first shows up. In later, more settled stages, central vision loss becomes more firmly established, and for a smaller number of patients, abnormal blood vessel growth beneath the retina can cause a further, sudden drop.
A fault in the BEST1 gene is behind this condition, a gene that ordinarily produces a protein called bestrophin-1 responsible for regulating the movement of ions and fluid across the retinal pigment epithelium. When that regulation breaks down, fluid and pigment collect abnormally beneath the macula, gradually shaping the lesion seen on examination. It follows a dominant inheritance pattern, though how strongly it shows up varies considerably — some carriers display a clearly visible lesion with barely any symptoms, while others in the same family face more meaningful changes to their vision.
An electro-oculogram carries most of the diagnostic weight here, typically coming back sharply abnormal — a low Arden ratio — even in an eye whose ordinary ERG trace looks unremarkable, and it's this particular mismatch that points a specialist toward Best disease rather than a lesion that merely resembles it. Repeat OCT imaging across successive visits charts how the deposit is progressing through its stages, and a confirmed BEST1 mutation both settles the diagnosis and flags which other family members might be quietly carrying the gene.
Given how long this lesion can sit without meaningful change, the early approach favours patient, staged observation over immediate intervention, with a particular eye kept on the modest but real chance of abnormal vessel growth as the lesion continues its slow evolution. Once a patient's vision has genuinely begun to suffer, regenerative stem cell therapy enters the conversation as part of a plan built around holding onto whatever central function is still there.
Yes, and it's actually a well-recognised, reassuring pattern in the early stage of Best disease. How large a lesion looks in a photograph has surprisingly little to do with how well a person actually sees, which is precisely why proper staging carries more weight than the drama of the image itself.
No — it remains a self-contained, benign condition confined entirely to the retina, with no link to cancer whatsoever. It does move through a series of recognised stages over time, though, and following that progression is precisely the reason for our ongoing monitoring.
That comes down to variable expressivity, a well-documented trait of BEST1 mutations. He could easily carry the identical faulty gene without it ever producing a visible lesion or symptoms — testing him directly is the only way to know for certain rather than assuming he's been spared.
No — a good number of patients hold onto reasonably strong central vision for many years, particularly those whose lesion never progresses past its earlier stages. Since that course genuinely differs from person to person, ongoing monitoring is what allows us to respond quickly the moment something does shift.